Stanford Medicine is the latest trial site to announce participation in the Pfizer vaccine nationwide clinical trial targeting children under 12 years of age. This study investigates the COVID-19 mRNA-based vaccine originally developed in Germany by BioNTech to determine the response in children. The prestigious university medical center will serve as a site for the Phase 2/3 clinical trial in a bid to determine if this vaccine can trigger an immune response in children from 5 years old up to 11 years of age. Stanford emerged as a trial site for a Phase 1 (safety trial) investigating the use of the vaccine at appropriate doses for children ages 6 months to five years of age. This Phase 1 trial already commenced, and the Phase 2-3 trial starts in mid-May. The studies have already fully enrolled, and the lead of the entire Stanford COVID-19 vaccination program for kids is on the record that these studies are needed to move to “herd immunity.”
By May 10, Stanford University News reported that the U.S. Food and Drug Administration (FDA) had already authorized the use of the vaccine for young people aged 12 to 15 years old in the United States.
The Pfizer vaccine i...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).